Clinical Trial Update: Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality [Phase 3]

View source ↗

Summary

Phase 3 trial of CUSA-081 for restoration of dysfunctional central venous access device functionality has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restoration of Function to Cvads

Drugs mentioned

• CUSA-081

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Restoration of Function to CVADs | Phase 3 | Status: WITHDRAWN